CSIMarket
 
Point Biopharma Global Inc   (NASDAQ: PNT)
 

Point Biopharma Global Inc's Customers Performance

PNT



 
PNT's Source of Revenues During the corresponding time, Point Biopharma Global Inc sequentially revenue fell by -42.66 %. While revenue at the Point Biopharma Global Inc 's corporate clients

List of PNT Customers




for the same period Point Biopharma Global Inc sequentially revenue fell by -42.66 %.

List of PNT Customers

Point Biopharma Global Inc's Business Units






Point Biopharma Global Inc's Comment on Sales, Marketing and Customers
















PNT's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Point Biopharma Global Inc 1,322.07 243.69 96.55 100
SUBTOTAL 0.00 0.00 0.00 -

Sources: Point Biopharma Global Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Point Biopharma Global Inc’s corporate clients.
For your research, we’ve provided 9 tables on Point Biopharma Global Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.